Neil Gallagher Sells 4,618 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Stock

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) insider Neil Gallagher sold 4,618 shares of the company’s stock in a transaction on Monday, February 10th. The shares were sold at an average price of $15.50, for a total transaction of $71,579.00. Following the sale, the insider now directly owns 85,095 shares in the company, valued at $1,318,972.50. This trade represents a 5.15 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Syndax Pharmaceuticals Price Performance

SNDX opened at $15.08 on Friday. Syndax Pharmaceuticals, Inc. has a fifty-two week low of $12.06 and a fifty-two week high of $25.34. The firm has a market capitalization of $1.29 billion, a PE ratio of -4.15 and a beta of 0.90. The company’s 50-day moving average is $13.96 and its 200 day moving average is $17.25.

Analysts Set New Price Targets

SNDX has been the topic of a number of research analyst reports. UBS Group started coverage on shares of Syndax Pharmaceuticals in a research report on Thursday, October 24th. They set a “buy” rating and a $37.00 price target on the stock. Citigroup upped their price objective on shares of Syndax Pharmaceuticals from $37.00 to $45.00 and gave the company a “buy” rating in a report on Tuesday, November 19th. Scotiabank dropped their price objective on shares of Syndax Pharmaceuticals from $18.00 to $16.00 and set a “sector perform” rating on the stock in a report on Wednesday, January 8th. The Goldman Sachs Group upped their price objective on shares of Syndax Pharmaceuticals from $30.00 to $33.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Finally, StockNews.com lowered shares of Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, November 23rd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $36.20.

Institutional Investors Weigh In On Syndax Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in SNDX. Simplify Asset Management Inc. increased its stake in Syndax Pharmaceuticals by 62.5% in the 3rd quarter. Simplify Asset Management Inc. now owns 122,185 shares of the company’s stock valued at $2,352,000 after buying an additional 46,992 shares during the last quarter. Franklin Resources Inc. increased its stake in Syndax Pharmaceuticals by 13.4% in the 3rd quarter. Franklin Resources Inc. now owns 1,763,277 shares of the company’s stock valued at $34,948,000 after buying an additional 208,043 shares during the last quarter. State Street Corp increased its stake in Syndax Pharmaceuticals by 4.1% in the 3rd quarter. State Street Corp now owns 3,770,826 shares of the company’s stock valued at $72,588,000 after buying an additional 148,491 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in Syndax Pharmaceuticals by 6.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 695,947 shares of the company’s stock valued at $13,397,000 after buying an additional 41,458 shares during the last quarter. Finally, Barclays PLC increased its stake in Syndax Pharmaceuticals by 143.4% in the 3rd quarter. Barclays PLC now owns 187,629 shares of the company’s stock valued at $3,612,000 after buying an additional 110,535 shares during the last quarter.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).